A Combination of Deworming and Prime-Boost Vaccination Regimen Restores Efficacy of Vaccination Against Influenza in Helminth-Infected Mice

Front Immunol. 2021 Dec 21:12:784141. doi: 10.3389/fimmu.2021.784141. eCollection 2021.

Abstract

Helminths still infect a quarter of the human population. They manage to establish chronic infections by downmodulating the immune system of their hosts. Consequently, the immune response of helminth-infected individuals to vaccinations may be impaired as well. Here we study the impact of helminth-induced immunomodulation on vaccination efficacy in the mouse system. We have previously shown that an underlying Litomosoides sigmodontis infection reduced the antibody (Ab) response to anti-influenza vaccination in the context of a systemic expansion of type 1 regulatory T cells (Tr1). Most important, vaccine-induced protection from a challenge infection with the 2009 pandemic H1N1 influenza A virus (2009 pH1N1) was impaired in vaccinated, L. sigmodontis-infected mice. Here, we aim at the restoration of vaccination efficacy by drug-induced deworming. Treatment of mice with Flubendazole (FBZ) resulted in elimination of viable L. sigmodontis parasites in the thoracic cavity after two weeks. Simultaneous FBZ-treatment and vaccination did not restore Ab responses or protection in L. sigmodontis-infected mice. Likewise, FBZ-treatment two weeks prior to vaccination did not significantly elevate the influenza-specific Ig response and did not protect mice from a challenge infection with 2009 pH1N1. Analysis of the regulatory T cell compartment revealed that L. sigmodontis-infected and FBZ-treated mice still displayed expanded Tr1 cell populations that may contribute to the sustained suppression of vaccination responses in successfully dewormed mice. To outcompete this sustained immunomodulation in formerly helminth-infected mice, we finally combined the drug-induced deworming with an improved vaccination regimen. Two injections with the non-adjuvanted anti-influenza vaccine Begripal conferred 60% protection while MF59-adjuvanted Fluad conferred 100% protection from a 2009 pH1N1 infection in FBZ-treated, formerly L. sigmodontis-infected mice. Of note, applying this improved prime-boost regimen did not restore protection in untreated L. sigmodontis-infected mice. In summary our findings highlight the risk of failed vaccinations due to helminth infection.

Keywords: Litomosoides sigmodontis; anthelmintic treatment; flubendazole; immunomodulation; influenza; parasite infection; prime-boost; vaccination efficacy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antinematodal Agents / administration & dosage*
  • Coinfection / immunology
  • Coinfection / parasitology
  • Coinfection / therapy*
  • Coinfection / virology
  • Disease Models, Animal
  • Female
  • Filariasis / immunology
  • Filariasis / parasitology
  • Filariasis / therapy*
  • Filariasis / virology
  • Filarioidea / immunology
  • Humans
  • Immunization, Secondary
  • Immunomodulation
  • Influenza A Virus, H1N1 Subtype / immunology
  • Influenza Vaccines / administration & dosage*
  • Influenza, Human / immunology
  • Influenza, Human / parasitology
  • Influenza, Human / therapy*
  • Influenza, Human / virology
  • Mebendazole / administration & dosage
  • Mebendazole / analogs & derivatives
  • Mice
  • Mites / parasitology
  • Sigmodontinae / parasitology
  • Vaccination / methods

Substances

  • Antinematodal Agents
  • Influenza Vaccines
  • Mebendazole
  • flubendazole